In the last trading session, 0.24 million shares of the Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) were traded, and its beta was 0.36. Most recently the company’s share price was $0.36, and it changed around $0.01 or 0.99% from the last close, which brings the market valuation of the company to $4.01M. CYCC currently trades at a discount to its 52-week high of $4.00, offering almost -1011.11% off that amount. The share price’s 52-week low was $0.31, which indicates that the current value has risen by an impressive 13.89% since then. We note from Cyclacel Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 12.33 million shares, with the 3-month average coming to 3.64 million.
Cyclacel Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 3.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 1 recommended CYCC as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Cyclacel Pharmaceuticals Inc is expected to report earnings per share of 0 for the current quarter.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) trade information
Instantly CYCC has showed a green trend with a performance of 0.99% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.4199 on recent trading dayincreased the stock’s daily price by 14.27%. The company’s shares are currently down -5.35% year-to-date, but still down -15.24% over the last five days. On the other hand, Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) is 3.67% up in the 30-day period. We can see from the shorts that 66765.0 shares have been sold at a short interest cover period of 0.03 day(s).
The consensus price target as assigned by Wall Street analysts is $1, which translates to bulls needing to increase their stock price by 64.0% from its current value. Analyst projections state that CYCC is forecast to be at a low of $1 and a high of $1.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32.13%.
CYCC Dividends
Cyclacel Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in February.
Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 4.82% of Cyclacel Pharmaceuticals Inc shares, and 18.03% of them are in the hands of institutional investors. The stock currently has a share float of 18.94%.
Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Nov 30, 2024 . The former held 8.96 shares worth $3188.0, making up 0.08% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 5.8 shares worth around $2062.0, which represents about 0.05% of the total shares outstanding.
